Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Amit Kumar Purchases 43,000 Shares

Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Amit Kumar purchased 43,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the transaction, the chief executive officer now owns 559,925 shares of the company’s stock, valued at $1,248,632.75. This trade represents a 8.32 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Anixa Biosciences Stock Performance

Shares of NASDAQ ANIX opened at $2.28 on Thursday. The firm has a fifty day moving average of $2.86 and a 200 day moving average of $3.03. The firm has a market cap of $73.37 million, a PE ratio of -5.85 and a beta of 0.82. Anixa Biosciences, Inc. has a one year low of $2.07 and a one year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. On average, equities analysts predict that Anixa Biosciences, Inc. will post -0.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ANIX shares. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently bought and sold shares of the company. Tyler Stone Wealth Management boosted its stake in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after acquiring an additional 21,008 shares during the last quarter. International Assets Investment Management LLC raised its stake in Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Westside Investment Management Inc. lifted its holdings in Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares in the last quarter. Concorde Asset Management LLC acquired a new stake in Anixa Biosciences during the 2nd quarter worth $31,000. Finally, Virtu Financial LLC purchased a new stake in shares of Anixa Biosciences during the third quarter worth $34,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.